Upon ligand-binding, the androgen receptor (AR) translocates from the cytosol to the cell nucleus, where it homodimerises to an active con®guration capable of transcriptional activation at promoter sites carrying an androgen response element (ARE) consensus sequence. The N-terminal region of AR contains speci®c activation function domains (AF) believed to be responsible for imparting cell and promoter speci®c functions to the receptor through recruitment of the transcriptional machinery. Its ability to do this may be facilitated by interaction with transcriptional factors termed co-activators. As such, coactivators may regulate AR activity at an individual promoter, as well as determine AR function in a speci®c cellular milieu. In the case of prostate cancer, androgen stimulation results in a mitogenic effect believed to be mediated through the AR. We hypothesised that unique co-activators regulate AR's growth stimulatory function in prostate cancer cells and, therefore, may serve as targets for therapeutic inactivation of AR.
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Method
In order to identify potential co-activators responsible for regulating AR-dependent growth in prostate cancer, we screened a library created from androgen-stimulated prostate cancer cells for proteins interacting with the AR N-terminal region using a modi®ed yeast 2-hybrid approach. We identi®ed 62 candidate proteins, termed ARTs for AR-trapped, which were then prioritised for characterisation based upon strength, speci®city, and location of interaction, homology to known genes, and expression in prostate cancer cell lines and tissues.
Results
To date, the most well-characterised of the ARTs is ART-27, which carries strong interaction af®nity for the AR N-terminal domain. In addition to the yeast 2-hybrid, we have demonstrated this interaction to occur in vitro upon translation of ART-27, suggesting it to be a direct interaction. The interaction maps to AR153-336, a region containing all of AF-1a and a small portion of AF-1b.
Overexpression of ART-27 in mammalian cells results in increased AR transcriptional activation. Furthermore, ART-27 enhances the transcriptional activity of a Lex A-AR153-336 fusion, but not of AR subdomains excluding the interacting region. In cells transfected with full-length AR, ART-27 overexpression increases the ligand potency of androgens, lowering the threshold of androgen necessary to achieve transcriptional activation.
Expression studies show ART-27 is expressed in a wide variety of normal human tissues, as well as in human prostate cancer cell lines PC-3, DU145, xenograft PC3416, and in an androgen-dependent fashion in LNCaP cells. Sequence evaluation reveals ART-27 to map to the Xp11 locus, previously described to be ampli®ed in a subset of hormone-refractory prostate cancers.
Conclusion
This, along with the results demonstrating a functionally signi®cant interaction with AR, supports the concept that ART-27 may be a regulator of prostate cancer growth and therefore serve as a potential therapeutic target. Current studies are focused upon the effects of ART-27 on prostate cancer growth utilising both ART-27 overexpressing stable prostate cancer cell lines and strategies to disrupt the ART-27/AR interaction in vivo. Additional functional studies are ongoing to characterise other strong interacting ARTs, speci®cally ART-5 and ART-37.
